ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

PURPOSE: DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Li, Qiang, Damish, Alexis W., Frazier, Zoë, Liu, David, Reznichenko, Elizaveta, Kamburov, Atanas, Bell, Andrew, Zhao, Huiyong, Jordan, Emmet J., Gao, S. Paul, Ma, Jennifer, Abbosh, Philip H., Bellmunt, Joaquim, Plimack, Elizabeth R., Lazaro, Jean-Bernard, Solit, David B., Bajorin, Dean, Rosenberg, Jonathan E., D’Andrea, Alan D., Riaz, Nadeem, Van Allen, Eliezer M., Iyer, Gopa, Mouw, Kent W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6434536/
https://ncbi.nlm.nih.gov/pubmed/29980530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi